{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:00:59Z","timestamp":1792036859515,"version":"4.4.0"},"reference-count":33,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015542","name":"GlaxoSmithKline Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of this noninterventional, retrospective ALFA study was to describe belantamab mafodotin effectiveness and safety in patients with relapsed\/refractory multiple myeloma in a real\u2010world setting in France.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Response rate, progression\u2010free survival (PFS), overall survival (OS), and safety were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 184 patients initiating belantamab mafodotin treatment, the overall response rate was 32.7% (\u2265very good partial response [VGPR] 20.4%, partial response [PR] 12.3%). The median PFS (mPFS) was 2.4\u2009months (95% confidence interval [CI]: 1.9, 3.3), and median OS (mOS) was 8.8\u2009months (95% CI: 6.3, 11.6). According to best response, mPFS was 20.6\u2009months (95% CI: 12.1, not reached [NR]) in patients with \u2265VGPR and 7.1\u2009months (95% CI: 4.6, 9.4) in patients with PR; mOS was NR in patients with \u2265VGPR and 17.5\u2009months (95% CI: 7.7, NR) in patients with PR. For both OS and PFS, no differences were found in subgroups of interest. The adverse events (AEs) reported in 159 patients (86.4%) were mostly ocular AEs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>ALFA, the largest real\u2010world cohort conducted so far, confirms the results of belantamab mafodotin as reported in the DREAMM\u20102 clinical trial. The clinical benefit is significant as long as the patient is a responder.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.14222","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T12:24:35Z","timestamp":1715257475000},"page":"310-320","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real\u2010world setting: The <scp>ALFA<\/scp> study"],"prefix":"10.1111","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4045-9428","authenticated-orcid":false,"given":"Murielle","family":"Roussel","sequence":"first","affiliation":[{"name":"Clinical Hematology and Cellular Therapy CHU Dupuytren  Limoges France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Texier","sequence":"additional","affiliation":[{"name":"Kappa Sant\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Nael","sequence":"additional","affiliation":[{"name":"Kappa Sant\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Bitetti","sequence":"additional","affiliation":[{"name":"GSK  Upper Providence Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prani","family":"Paka","sequence":"additional","affiliation":[{"name":"GSK  Upper Providence Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naima","family":"Kerbouche","sequence":"additional","affiliation":[{"name":"GSK  Rueil\u2010Malmaison France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Sail","sequence":"additional","affiliation":[{"name":"GSK  Rueil\u2010Malmaison France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Colin","sequence":"additional","affiliation":[{"name":"GSK  Rueil\u2010Malmaison France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"name":"Department of Hematology CHU, Poitiers  Poitiers France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13976"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.380"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.867"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.508"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0196-6"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33809"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"e_1_2_11_11_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9.BLENREP (belantamab mafodotin). Haute Aut Sant\u00e9 [Internet]. Accessed June 7 2023.https:\/\/www.has-sante.fr\/jcms\/p_3224946\/fr\/blenrep-belantamab-mafodotin"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00592-3"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-022-00212-5"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1026251"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18479"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281772"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1082"},{"key":"e_1_2_11_19_1","unstructured":"Official Journal of the European Communities.Directive 95\/46\/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data. 281(No L 281\/31). Accessed November 22 2022.http:\/\/data.europa.eu\/eli\/dir\/1995\/46\/oj\/eng"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-156035"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000521"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.013"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00432-4"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8007"},{"key":"e_1_2_11_25_1","unstructured":"Food and Drug Administration.GlaxoSmithKline Intellectual Property Development Ltd. England; Announcement of the Revocation of the Biologics License for BLENREP.2023Accessed January 15 2024.https:\/\/www.federalregister.gov\/documents\/2023\/03\/30\/2023\u201006576\/glaxosmithkline\u2010intellectual\u2010property\u2010development\u2010ltd\u2010england\u2010announcement\u2010of\u2010the\u2010revocation\u2010of\u2010the"},{"key":"e_1_2_11_26_1","unstructured":"European Medicines Agency.EMA confirms recommendation for non\u2010renewal of authorisation of multiple myeloma medicine Blenrep. Accessed January 11 2024.https:\/\/www.ema.europa.eu\/en\/news\/ema-confirms-recommendation-non-renewal-authorisation-multiple-myeloma-medicine-blenrep"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.36_suppl.439572"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147101"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-173064"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112948"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14222","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T09:01:17Z","timestamp":1727773277000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1111\/ejh.14222"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14222","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,9]]},"assertion":[{"value":"2023-12-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}